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ABSTRACT
INFLAMMATORY CELL TUMOR NECROSIS FACTOR SIGNALING
MODULATES POST-INFARCTION LEFT VENTRICULAR REMODELING

Robert Kenneth Lewis
December, 2010

The fundamental question of the exact nature of the role played by TNF in the
failing myocardium remains one of contention.

Many preclinical studies have

demonstrated beneficial effects with TNF antagonism and recently the
dichotomous role played by the two TNF receptors in chronic ischemic injury has
come to light. The failing heart has also been determined to have low levels of
inflammatory cell infiltration. As these cells are known to be potent producers of
inflammatory cytokines, we hypothesized that inflammatory cell localized TNF
receptors play an important role in the progression of LV remodeling following
ischemic injury. To isolate the in vivo effects of inflammatory cell TNF receptors,
we generated chimeric mice. Wild-type (WT, C57BLl6) mice underwent radiationinduced bone marrow (BM) ablation followed by reconstitution with BM from WT
mice (WTc control, n=30), TNFR 1-/- mice (R1-/-c, n = 30) or TNFR2 -/- mice
(R2-/-c, n = 30). Six weeks later, WTc, R1-/-c, and R2-/-c mice were subjected to
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coronary ligation to induce heart failure (HF) or sham operation. Our results
demonstrated that compared to WTc sham, 4 weeks after surgery, WTc HF
hearts exhibited significantly (p < O.OS): 1) increased LV size (EDV 96.7 ±. 13.7
vs. 26.6 ± 8.2 IJL) and dysfunction (LVEF 2S.S ± 7.S vs. 69.8 ± 4.S%); 2) greater
hypertrophy (LV/tibia length [TL] 3.91 ± 0.S3 vs. 2.9 ± 0.4, -4-fold greater atrial
natriuretic factor [ANF] mRNA); 3) increased fibrosis (16.10 ± 8.16% vs. 1.4 ±
0.4%) and connective tissue growth factor (CTGF) mRNA expression, and 4)
increased (-2-fold) mRNA levels of TNF, interleukin (IL)-1j3, and IL-6. WTc HF
mice also had markedly reduced survival (60% vs. 100%) and increased blood
levels of activated F4/80+/CD11 b+ monocytes vs. WTc sham mice. In contrast,
compared to WTc HF, R1-1-c HF mice exhibited significantly (p < O.OS): 1)
improved survival (80%), 2) less LV dilatation and improved LVEF (42.9 ± 4.2%),
3) less cardiac hypertrophy (LVITL 3.14 ± 0.2) and ANF mRNA expression, 4)
less cardiac fibrosis (S.48 ± 2.26%) and CTGF mRNA expression, and S) less
cardiac TNF and IL-1j3 mRNA expression. Also, compared to WTc HF, R2-/-c HF
mice exhibited significantly (p < O.OS) greater circulating F4/80+/CD11 b+
monocytes (1S.32 ± 4.41 vs. 12.1 ±1.24%), and greater cardiac fibrosis (21.92 ±.
10.81%). Also noted was an increase, although not significant, in EDV and ESV.
In parallel in vitro studies, the contribution of inflammatory cell TNFR1 and
TNFR2 (Le.,

macrophage-derived) to cardiac contractile dysfunction was

investigated.

Macrophages isolated from WT mice with HF 4 week post-

infarction, when co-cultured with na"lve cardiomyocytes induced contractile
dysfunction and myocyte reactive oxygen species (ROS) generation in a
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juxtacrine but not paracrine maner (p<O.001).

Interestingly the effect on

contractile dysfunction was diminished with the loss of TNFR1 in the HF
macrophages but remained unchanged upon loss of TNFR2.

Of note, ROS

production in these groups followed a similar pattern in that loss of TNFR1
resulted

in

significantly attenuated

myocyte

macrophage contact with na"lve myocytes.
inflammatory cell-localized TNF

ROS

production

upon

HF

We therefore conclude that

receptor signaling

has fundamental

yet

dichotomous, roles in post-infarction LV remodeling. In that inflammatory cell
TNFR1 is required for the production of the pro-inflammatory state in failing
myocardium and exacerbates post-infarction remodeling.

Moreover, TNFR1

signaling in macrophages in HF augments macrophage-induced contractile
dysfunction and ROS generation. Inflammatory cell-localized TNFR2 signaling
has modest antifibrotic effects in the failing heart. TNF-dependent inflammatory
cell responses are critical for the progression of pathological remodeling in HF.
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CHAPTER I

INTRODUCTION

Several complex pathophysiologic mechanisms influence the process of left
ventricular (LV) remodeling in chronic heart failure (HF). These include changes
in mechanical forces, such as wall stress and increases in systemic vascular
resistance, creating afterload mismatches, inflammatory cytokine production
particularly TNF, IL-1, and IL-6, and activation of neurohormonal signaling
pathways, most importantly the renin-angiotensin system and the sympathetic
nervous system [1-8]. (Figure 1)

These responses initially help compensate for the acute phase of myocardial
injury and its physiological consequences. For example, increased salt and fluid
retention mediated by angiotensin and increases in systemic vascular resistance
and heart rate driven by the sympathetic nervous system serve to maintain blood
pressure and cardiac output, facilitating organ perfusion. In the chronic HF state,
however, these responses become detrimental, creating a milieu that precipitates
the undesirable consequences of myocyte apoptosis, mitochondrial dysfunction,

myocyte hypertrophy, and contractile dysfunction [9-12]. This ultimately results
in LV remodeling grossly evident by chamber dilatation [2-6]. On the molecular
level, the phenotype of HF includes activation of the fetal gene program [1,13].
abnormalities of calcium handling [14-18]. uncoupling of 13-adrenergic receptor
(l3-AR) signaling [19-21], reactive oxygen species (ROS) production [10,22-26],
and activation of inflammatory pathways. These pathological changes are
characteristic phenotypic features of HF, and thus can be used as physiological
indices of the severity of cardiac dysfunction and remodeling.

Myocardial Injury
Loss of Contractil. Units
Compensatory Responses
Neurohormonal Activation
Inflammatory Cytokines
Growth Factors

Inflammatory Activation

Fetal Gene Program
Hypertrophy

1

I Oxidative Stress I
Fig1: Pathological mechanisms of LV remodeling after myocardial injury [13]

As mentioned above, inflammation is a hallmark of chronic HF [27,28]. Elevated
levels of pro-inflammatory cytokines such as TNF, interlukin-113 (IL-1 A and
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interlukin-6 (IL-6) are present at high levels in the plasma of HF patients.
Interestingly, the level of these cytokine correlates inversely with survival [29-31].
Moreover, levels of the anti-inflammatory cytokine interleukin-10 (lL-10) have
been observed to be significantly reduced in chronic HF patients [32-35].
Elevated levels of pro-inflammatory cytokines have not only been observed
systemically but in the injured myocardium as well.

Together these findings

delineate the pro-inflammatory imbalance in patients with chronic HF [29, 36-38].
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CHAPTER II

BACKGROUND

Why would TNF matter in Heart Failure?

Several lines of evidence point to TNF as a potential target of therapeutic interest
in chronic HF. First, elevated plasma levels of TNF and IL-6, as well as soluble
TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2) function as independent
predictors of mortality in HF patients [31,39,40]. Secondly, in experimental animal
models, TNF via infusion or over expression, can reproduce many of the
phenotypic responses noted in HF, specifically depressed contractile function
[41-43], myocyte hypertrophy [28,44], P-AR uncoupling [43], apoptosis [45], and
ROS production [46] indicating that TNF in sufficient levels, even in the absence
of antecedent injury, can decrease myocardial performance. Third, mice with
cardiac-specific TNF over-expression suffer a premature death with a dilated
cardiomyopathy, characterized by many of the same pathologic findings seen in
chronic ischemic HF [47-49].

Fourth, while it is true that several pro-

inflammatory cytokines are up regulated in the setting of HF, TNF is a foundation
cytokine, that has the ability to modify the expression of others such as IL-1 P and
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IL-6 [50,51]. Lastly, antagonism of TNF in several animal models including TNF
infusion [5], cardiac specific TNF over expression [52], and in post infarction HF
[53-57] ameliorates the deleterious effects of pro-inflammatory milieu seen with
the preceding conditions.

Clinical Trials: What Happened?

The findings of the above mentioned animal studies created a great deal of
enthusiasm in the HF community. Hurried enthusiasm led to the initiation of
clinical studies to test the effectiveness of TNF antagonism in chronic HF. Two
forms of TNF antagonism where used. The first was etanercept, a previously
FDA-approved drug for use in the chronic inflammatory condition of rheumatoid
arthritis, consisting of two TNFR2 receptors linked to human IgG1 :Fc. The
second drug was infliximab, composed of anti-TNF murine Fab linked to human
IgG1:Fc. This drug was also FDA-approved for human usage prior to the HF
trials for the same indication as entanercept. The four clinical trials where named
RECOVER, RENAISSANCE, RENEWAL, AND ATTACH. Each independently
reached conclusions that put the HF community in flux. Interestingly these trials
showed no beneficial effect from TNF antagonism and concluded that both
increased deaths and HF hospitalizations occur in a time and dose dependent
manner in response to TNF antagonists [28,50,58]. This of course was quite
surprising given the promising nature of the pre-clinical data, and begged the
question, why the dichotomous results? Why did the clinical trials prove to be
such a disappointment?

While the true reason is yet undefined, several
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hypotheses have been proposed [28,50,58] to explain the surprising findings.
The most popular of the possible explanations is poor study design. While this
always seems to be the first criticism put forth when things don't go as planned,
there is likely some validation for this claim. Many investigators argue that these
trials were plagued by the selection of patients with disease so advanced they
where unlikely to recover, improper drug dosing both in quantity given and timing,
and poorly defined end points. A second possible explanation is that the side
effects of the drugs used were not completely understood, and that some of the
toxicity observed had nothing to do with myocardial TNF interaction, but was
related to the inherent pharmacologic properties of the drugs themselves. Lastly
and perhaps most intriguing is that role of TNF in HF is more complicated and
diverse

than

previously

believed,

and

a deeper

and

more

profound

understanding of the complex and wide ranging interactions of TNF was needed
before we could understand the proper use of TNF antagonism in chronic HF.

The complicated nature of TNF

It is known that TNF, along with other pro-inflammatory cytokines, is an
evolutionarily well-conserved stress response molecule.

From an intuitive

standpoint, the highly-conserved nature implies an element of usefulness. In the
myocardium, TNF provides protection during the acute phase of ischemic injury
[59,60], and during infective myocarditis [61,62]. TNF may have multi-faceted
effects in the heart that produce either adaptive or maladaptive responses based
on a delicate balance of cytokine and receptor expression. Previous work,
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discussed later, has shown that there is a dichotomous effect in the failing
myocardium that is TNF receptor dependent [63].

To fully grasp the effects of TNF, it is important to understand its signaling
mechanisms.

TNF is expressed as both a soluble molecule (sTNF) and in a

membrane bound form (mTNF) [64-69]. Likewise, TNF signaling occurs through
two cell surface receptors, TNF receptor 1 (TNFR1) and TNF receptor 2
(TNFR2).

Neither receptor possesses enzymatic activity, and as a result

signaling involves recruitment of additional intracellular proteins. TNFR1 binding
and activation results in the recruitment of: 1) TNF receptor associated death
domain (TRADD) ultimately resulting in the activation of caspase dependent
apoptosis, and 2) TNF receptor-associated factor 2 (TRAF2) through the TRADD
leading to the activation of nuclear factor- kappa B (NF-KB), c-Jun N-terminal
kinase (JNK) phosphorylation leading to activation of activator protein-1 (AP-1),
and p38 mitogen activated protein kinase (MAPK) activation.

There is a

significant amount of cross talk between the two receptors and their downstream
signals [64-67].

However, TNFR2 does not bind to the TRADD but instead

directly activates TRAF2 resulting in the same activation of NF-KB, AP-1, and
p38 MAPK. (Figure 2) TNFR1 and TNFR2 also differ in their response to the
different forms of TNF that serves to activate these receptors. Whereas TNFR1
is activated equally by both sTNF and mTNF forms, TNFR2 is activated
predominantly by mTNF [64,65,67,70]. Most of the in-vitro studies that define cell
signaling use sTNF, and under these conditions TNFR2 is not activated to any
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significant extent. Because of this, TNFR2 intracellular mechanisms are not as
clear as those of TNFR1, and hence the benefits and consequences of its
signaling mechanisms are not as well delineated .

Figure 2: TNFR1 and TNFR2 signaling mechanisms. [66]

The heart normally expresses equal amounts of TNFR1 and TNFR2. However,
during the normal homeostatic state, there is no constitutive myocardial
expression of TNF in either the membrane bound or soluble form [29,71]. In the
failing heart, however, there is significant expression of TNF and a substantial
but equal down regulation of both TNF receptors to approximately one-half of
their constitutive expression [29] . This is, of course, not an uncommon response
to a dramatic and chronic increase in receptor stimulation. There is also a
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substantial increase in soluble TNF receptor levels in the serum of HF patients,
possibly indicating a mechanism by which TNF responses are modulated [29].

In vivo, TNF can produce its effects in a juxtracrine manner, i.e. cell-to-cell
physical contact.

These interactions are more dependent on mTNF than the

soluble form. Moreover, the dichotomy in the functional activation of the two TNF
receptors in experimental models suggests either mTNF or sTNF over
expression.

In models of cardiac specific mTNF over-expression, resulting in

primarily TNFR2 activation, concentric hypertrophy LV occurs, whereas in sTNF
over-expression models, the animals develop a dilated cardiomyopathy [72].
Further evidence of divergent phenotypic responses is seen in disease states
involving organ systems other than the myocardium.

In a model of retinal

ischemia, signaling through TNFR1 results in a worse phenotype [73]. On the
other hand TNFR2 is primarily responsible for the detrimental effects of TNF in
inflammatory arthritis as well as inflammatory bowel disease (IBD) [74].

Inflammatory cells are the major source of TNF production in the baseline state
[64].

These cells also serve as an important source of pro-inflammatory

cytokines during chronic HF, producing significantly elevated levels of TNF [75].
There is also progressive macrophage infiltration observed in the failing
myocardium

that

positively

correlates

with

disease severity

[36,76-80].

Furthermore, co-localization of IL-1j3 and TNF occur in these infiltrating cells
[36,76,78] demonstrating their active nature. These cells not only invade the
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failing myocardium but are activated, producing pro-inflammatory cytokines and
exerting detrimental effects in the heart. Furthermore, in an ischemic HF model,
the administration

of an

dramatically reduced

inhibitor of monocyte!

myocardial

expression

macrophage activation

of TNF,

demonstrating the

significant contribution of these cells to cardiac TNF production in HF [81]. To
this point, differential cell-type specific responses occur with cytokine stimulation
[64,66]. Inflammatory cells release a host of cytotoxic mediators with cytokine
stimulation [82,83] that may affect adjacent cells [84].

One example is the

release of nitric oxide (NO) from stimulated macrophages leading to superoxide
generation and peroxnitrite formation [85-88]. To further support the importance
of the inflammatory cell's interaction with the heart, studies of endotoxemia show
that inducible NO synthase (iNOS) from inflam matory cells, and not myocytes, is
responsible for myocardial dysfunction in sepsis [84,89].

Unraveling the mystery

Previous work in the Prabhu lab further delineate the possibility of a dichotomous
relationship between the two TNF receptors in chronic HF that is apparent in
extracardiac disease processes.

This work shows that somatic TNFR1 and

TNFR2 null mice exhibit disparate effects on many of the hallmark phenotypical
findings in chronic HF, specifically LV remodeling and myocyte hypertrophy,
when subjected to permanent coronary ligation [63].
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To obtain this initial data, TNFR1-/- and TNFR2-/- mice were compared to
C57BL6 mice after undergoing either permanent left coronary artery ligation to
induce HF or sham operation.

As expected, the C57BL6 mice exhibited

significant LV dilatation and dysfunction.

However, these detrimental effects

were alleviated in TNFR1-1- mice (unopposed TNFR2 stimulation). Interestingly,
TNFR2-/- mice (unopposed TNFR1 stimulation) demonstrated an exaggerated
remodeling response to chronic ischemic injury [63].

The above observations suggest that TNFR1 and TNFR2 have divergent effects
on the pathological remodeling in HF, in that TNFR1 augments and TNFR2
attenuates this process.

Furthermore, as activated inflammatory cells impart

significant toxic cytokine-mediated responses on adjacent tissues, it is also likely
that the TNFRs would demonstrate divergent and opposing phenotypic
responses in HF if modulated in the inflammatory compartment.

I seek to define an integrated model of TNFRs and activated macrophages in the
failing myocardium. I propose, as shown in Fig 3, a hypothesis that in activated
macrophages infiltrating the failing heart, TNFR1 increases whereas TNFR2
opposes, or at least does not exacerbate, cellular activation as well as toxic
metabolites and cytokine production.

These changes serve to affect, in a

dichotomous manner based on TNFRs, adjacent myocyte function and LV
remodeling in response to ischemic injury.
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CHAPTER III

FUNDAMENTAL QUESTION

Phenomenon: Several pre-clinical and clinical studies have been undertaken to

delineate the role of TNF in chronic HF. While the pre-clinical animal studies of
TNF antagonism have been overwhelmingly positive, the clinical studies with
TNF antagonist proved not only negative, but demonstrated an increase in

morbidity and mortality. Hence, the precise role of TNF as a therapeutic target in
HF remains yet undetermined.

Proposed concepts: Fundamental questions remain regarding the role of TNF

in chronic HF.

Previously the Prabhu lab demonstrated a dichotomous role for

TNF in chronic murine HF dependent on the receptor stimulated, TNF receptor 1

or receptor 2.

This could perhaps explain some of the conflicting data observed

in the pre-{;Iinical and clinical studies.

Given, however, that a substantial

percentage of the TNF produced during an inflammatory state is a product of
inflammatory celis, and that pro-inflammatory cytokines have been determined to
playa substantial role in the pathology of HF, it is possible that TNF exhibits both
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temporal, i.e. early vs. late HF, and spatial, i.e. somatic vs. inflammatory cell
differences, that further determine the complex nature of TNF in chronic HF.

Experimental design: To determine the role of TNF in HF, an experimental
protocol was designed to test the following hypothesis.

Hypothesis:
TNF has complex and dichotomous effects based on the TNF receptor
stimulated.

Likewise, inflammatory cells and their products play an

important and deleterious role in the propagation of the pathology
associated with chronic HF.

I propose that selective modulation of the

TNFRs in the inflammatory compartment will result in phenotypic
differences in chronic ischemic heart failure. The ablation of TNFR1 will
result in beneficial changes and the loss of TNFR2 will serve to further
worsen the HF phenotype or possibly have no effect, if the primary
detrimental effects are mediated by TNFR1. (Figure 3)

Aim #1: To define the in vivo role of the inflammatory cell, as opposed to the
myocyte, with regards to the divergent TNFR-specific effects in post-infarction LV
remodeling.

Aim#2: To delineate the role of the TNF receptor in in vitro macrophage-myocyte
interactions in the setting of heart failure.
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LV Remodeling
Myocyte Dysfunction

Figure 3: Graphical representation of the hypothesis for AIM 1. In response to ischemic injury activated
macrophages infiltrate the myocardium. These macrophages assert their effects in a TNF dependent
manner based on a dichotomous relationship between TNFR1 and TNFR2. TNFR1 increases whereas
TNFR2 opposes cellular activation as well as toxic metabolite and cytokine production. These changes
serve to effect adjacent myocyte function and LV remodeling in response to ischemic injury.
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CHAPTER IV

AIM #1: TO DEFINE THE IN VIVO ROLE OF THE INFLAMMATORY CEll, AS
OPPOSED TO THE MYOCYTE, WITH REGARDS TO THE DIVERGENT TNFRSPECIFIC EFFECTS IN POST-INFARCTION lV REMODELING.

BRIEF PREVIEW

Background:

Elevated myocardial and systemic levels of inflammatory

mediators are hallmarks of chronic heart failure (HF) and predictors of mortality.
Tumor necrosis factor-a (TN F), a "foundation" cytokine that influences other
inflammatory mediators, is considered to play a detrimental role in the
pathogenesis of LV remodeling.

However, large multi-center clinical trials of

biological anti-TNF therapy in HF have been negative, demonstrating no effects
or even increased mortality with such therapy. This suggests that the effects of
TNF are not homogeneous, and are more complex than an all-or-none toxic
response in the failing heart. TNF signals through two cell-surface receptors,
TNFR1 and TNFR2.

TNF induces divergent inflammatory and remodeling

responses in the failing heart that are TNF-receptor specific: TNFR1 signaling is
detrimental and promotes these effects, whereas TNFR2 signaling is beneficial
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and opposes these effects. Importantly, in addition to myocyte-specific effects,
TNF also activates immune and inflammatory cells that are potential sources of
cytokines and cellular toxicity in HF. However, the importance of inflammatory
cell-localized TNF responses in the pathogenesis of LV remodeling is unknown

Hypothesis:

Inflammatory cell-localized TNFR1 and TNFR2-signaling play

important and divergent roles in the progression of post-infarction LV remodeling
in chronic HF.

My study objective was to evaluate the effects of selective

inflammatory/immune cell TNFR1 or TNFR2 ablation on LV remodeling

Methods: In order to delineate the role of immune cell TNFR1 and TNFR2 in LV

remodeling chimeric mice were generated.

Recipient WT C57BLl6 mice

underwent lethal bone marrow irradiation followed by reconstitution with bone
marrow from either TNFR1 -/- or TNFR2 -/- mice.
marrow from C57BLl6 were used as a control.

Reconstituted with bone

Mice were quarantined for 30

days post-transplant to ensure adequate resident cell turnover, and chimerism
was confirmed via flow cytometery of donor CD45.2 and recipient CD45.1. All
mice exhibited more than 90% marrow chimerism.

Mice were evaluated at

baseline and sequential time points via echocardiography and flow cytometry.
Phenotypic assessment with a variety of physiologic, histologic, and molecular
techniques was performed as discussed in detail in the Methods section.
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Results: These mice, which exhibit loss of either TNFR1 (R1-/-c) or TNFR2
(R2-/~)

or loss of neither receptor (WTc) in inflammatory cells, underwent

coronary ligation to induce HF or sham operation. Compared to WTc sham, 4
weeks after surgery, WTc HF hearts exhibited significantly (p < O.OS): 1)
increased LV size (EDV 96.7 ±. 13.7 vs. 26.6 ± 8.2 IJL) and dysfunction (LVEF
2S.S ± 7.S vs. 69.8 ± 4.S %); 2) greater hypertrophy (LV/tibia length [TL] 3.91 ±
0.S3 vs. 2.9 ± 0.4, -4-fold greater atrial natriuretic factor [ANF] mRNA); 3)
increased fibrosis (16.10 ± 8.16% vs. 1.4 ± 0.4 %) and connective tissue growth
factor (CTGF) mRNA expression, and 4) increased (-2-fold) mRNA levels of
TNF, interleukin

(IL)-1~,

and IL-6. WTc HF mice also had markedly reduced

survival (60% vs. 100%) and increased blood levels of activated F4/80+/CD11b+
monocytes vs. WTc sham mice. In contrast, compared to WTc HF,

R1-/~

HF

mice exhibited significantly (p < O.OS): 1) improved survival (80%), 2) less LV
dilatation and improved LVEF (42.9 ± 4.2 %),3) less cardiac hypertrophy (LVITL
3.14 ± 0.2 mg/mm) and ANF mRNA expression, 4) less fibrosis (S.48 ± 2.26 %
area) and CTGF mRNA expression, and S) less cardiac TNF and

IL-1~

mRNA

expression. Also, compared to WTc HF, R2-/-c HF mice exhibited significantly (p
< O.OS) greater circulating F4/80+/CD11 b+ monocytes (1S.32 ± 4.41 vs. 12.1

±1.24 % gate), and greater cardiac fibrosis (21.92 ±. 10.81 % area). Also noted
was an increase, although not significant, in EDV and ESV.

Conclusion:

Inflammatory

cell-localized

TNFR1

signaling

exacerbates

inflammation and cardiac remodeling in HF, whereas inflammatory cell TNFR2
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signaling has modest anti-fibrotic and anti-inflammatory effects. Modulation of
global inflammatory cell function induces profound localized alterations in LV
remodeling; TNFR1/R2 signaling plays an important role in these effects.
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INTRODUCTION

It is well established that inflammation is one of the key mediators of the
deleterious effects seen in chronic HF [27,28].

Elevated levels of pro-

inflammatory cytokines such as TNF are present in the plasma and myocardium
of HF patients. Interestingly, levels of these cytokines correlate inversely with
survival in chronic HF [29-31]. Collectively, these findings delineate that there is
a pro-inflammatory imbalance in chronic HF, and that this imbalance plays a
substantial role in the progression of disease [29, 36-38].

Several lines of evidence point to TNF as a potential target of therapeutic interest
in chronic HF.

First, as mentioned above, elevated plasma levels of TNF

function as independent predictors of mortality in HF patients [31,39,40].
Secondly, in experimental animal models, TNF infusion or over-expression
reproduces many of the phenotypic responses noted in HF [28,41-46].

Also,

TNF has been shown to be a foundation cytokine in that has the ability to modify

the expression of the other pro-inflammatory cytokines such as IL-113 and IL-6
[50,51].

Lastly, antagonism of TNF in several animal models, including TNF

infusion [5], cardiac specific TNF over-expression [52], and in post-infarction HF
[53-57], ameliorate the deleterious effects of the pro-inflammatory milieu seen in
these conditions.
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The above findings led to the initiation of clinical studies of TNF antagonism in
chronic HF patients. Interestingly these trials not only failed to show beneficial
effects, but also that TNF antagonism increased death and HF hospitalization in
a time and dose dependent manner [28, 50]. This of course was quite surprising
given the robust pre-clinical data showing the very promising possibilities for TNF
modulation. These results raised the question as to why the clinical trials prove
to be such a disappointment? Perhaps the role of TNF in HF is more complicated
and diverse than previously believed. TNF may in fact have multi-faceted effects
in the heart that can produce either adaptive or maladaptive responses based on
a delicate balance of cytokine and receptor expression.

Previous work has

proven that in fact there is a dichotomous effect in the failing myocardium which
is TNF receptor dependent [63].

The primary sources of TNF in the quiescent state are monocytes and
macrophages [64]. Likewise, these cells also serve as an important source of
pro-inflammatory cytokines in HF, producing significantly elevated levels of TNF
and other mediators of inflammation [75].

There is progressive macrophage

infiltration observed in the failing myocardium that positively correlates with
disease progression [36,77-80]. Furthermore, co-localization of IL-1 ~ and TNF
has been demonstrated in these infiltrating cells [36,78]. Likewise in an ischemic
HF model, administration of an inhibitor of monocyte/macrophage activation
dramatically reduced

myocardial

expression of TNF,

demonstrating the

significant contribution of these cells to cardiac TNF production in HF [81].
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Previous work in our lab has shown that TNFR1 and TNFR2 whole body knock
out (-1-) animals exhibit disparate effects on post-infarction LV remodeling,
hypertrophy, inflammation, and apoptosis [63]. This would suggest that TNFR1
and TNFR2 have divergent effects in HF in regards to the primary responses
mediated by TNF, namely inflammation and myocardial dysfunction, in that
TNFR1 augments while TNFR2 attenuates these processes.
activated

inflammatory cells

Furthermore, as

impart significant toxic cytokine

medicated

responses on adjacent tissues, it is possible that the TNFRs could impart
analogous divergent and opposing phenotypic responses in HF if modulated in
the inflammatory compartment.

I seek to define an integrated model of TNFRs and activated macro phages in the
failing myocardium. I propose, as shown in Figure 3, a hypothesis that in cardiac
macrophages, TNFR1 increases whereas TNFR2 opposes, or at least does not
exacerbate, cellular activation as well as toxic metabolite and cytokine
production. These changes serve to affect, in a dichotomous manner based on
TNFRs, adjacent myocyte function and LV remodeling in response to ischemic
injury.
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MATERIALS AND METHODS

Animals and Generation of Chimerjc Mice.

Recipient C57BLl6 mice (8-12

wks, 20-25 grams) were irradiated overnight (950 cGy) in an irradiation chamber
to ablate the bone marrow compartment (Figure 4). The following day, femur
bone marrow was harvested from donor green fluorescent protein (GFP)
expressing transgenic (Tg) mice, WT C57BLl6 control, TNFR1- 1-, or TNFR2- 1(Jackson Labs) mice. 15 x 106 cells of donor bone marrow were injected via tail
vein into recipient mice. Mice were quarantined for 30 days to ensure adequate
resident cell turnover. Post-quarantine, flow cytometric analysis of donor CD45.2
fluorescein isothiocyanate (FITC) vs recipient CD45.1 phycoerythrin (PE) was
performed to determine percent chimerism. All study mice exhibited greater than
90% chimerism.

Briefly, for GFP Tg mice, a bacterial artificial chromosome

(BAC) encoding the mouse Rag1 and Rag2 sequence was modified by the
insertion of an enhanced green fluorescent protein gene into exon 1 of Rag2.
TNFR 1-1- was achieved via insertion of a neomycin cassette at position 535 of the
coding sequence on chromosome 6 [90]. For TNFR2-1- generation, homologous
recombination techniques to target the Tnfr2 gene where used. Specifically, a
construct containing a neomycin resistance gene under the control of the Pgk
promoter was inserted into the second exon of the Tnfr2 gene resulting in loss of
gene function [91].
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Figure 4. A: Bone marrow chimeric mice were generated by ablation of donor C57BU6
mouse marrow via ovemight irradiation followed by reconstitution with either TNFR1-f-,
TNFR2-/- or C57BU6 marrow. B : Chimerism was confirmed by flow cytometric analysis of
donor CD45.2-FITC and recipient CD45.1-PE demonstrating greater then 90% chimerism.

Coronary ligation and experimental protocol, All studies were performed in
compliance with the NIH Guide for the Care and Use of Laboratory Animals
(DHHS publication No. [NIH] 85-23, revised 1996). Permanent coronary ligation
was performed as previously described [63 ,92] Anesthesia was induced in mice
with tribromoethanol (0.25 mg/g IP). After induction , the mice were intubated and
supported with a MiniVent Mouse Ventilator (Type 845, Harvard Apparatus) at
125-150 breaths/minute depending on body weight (tidal volume 6.4 !JUg , PEEP
5-7 cm H20). Anesthesia was maintained with 1% isoflurane. Heat lamps and
heating pads were used to maintain body temperature at 3rC. Under sterile
conditions, a left thoracotomy was performed in the 4th intercostal space , the
heart exposed , and the pericardium opened . An 8.0 prolene ligature was passed
and tied around the proximal left coronary artery, 1 mm distal to the left atrial
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appendage border. Successful occlusion was confirmed by the production of
pallor and dyskinesia in the distal myocardium. In sham animals, the suture was
passed but not tied. The chest was then closed in layers using 5.0 silk, and the
mice were allowed to recover. The total mice used for these studies were as
follows: WTc n = 30; R1-/-c n = 30; R2-/-c n = 30. Mice were followed for 4 weeks
following operation.

Echocardiography.

Under

tribromoethanol

(0.25

mg/g

IP)

sedation,

echocardiography (M-mode, 2D, and Doppler) was performed at baseline and 4
weeks post-operatively using a Philips Sonos 5500, 15 MHz linear array
transducer, 120 Hz frame rate. Measured variables included the short-axis enddiastolic (ED) and end-systolic (ES) diameter (D) and wall thickness (WT), and
long-axis end-diastolic and end-systolic volume (EDV and ESV) using the
modified Simpson's method. LV systolic function was indexed by either fractional
shortening (FS = EDD-ESD/EDD) or single plane planimetered LV ejection
fraction (EF = EDV-ESV /EDV).

Histomorphometry and immunohistochemical analysis. Paraffin embedded

tissue sections (5IJm) were de-paraffinized, rehydrated, and stained with Masson
Trichrome (for collagen) using standard histologic techniques [63,92]. The
degree of tissue fibrosis (blue-green stain) was assessed using Metamorph
Imaging Software.
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Wheat Germ Agglutin (WGAl staining.

Paraffin embedded tissue sections (5

1lrTl) were de-paraffinized and rehydrated. They were then stained with WGA
solution diluted to 5 Ilg/ml in PBS for 1 hour in a dark room at room temperature.
The slides were washed and fixed with DAPI Antifade Reagent and sealed. Epifluorescent microscopy (Nikon TE 200) was used for analysis.

Real-time peR and mRNA guantitation.

Total RNA was isolated from LV

tissue using TRlzol reagent (Invitrogen), and cDNA was synthesized from 1 I-Ig
RNA using the iScripFM cDNA Synthesis kit (BioRad). Relative levels of mRNA
transcripts for atrial natriuretic factor (ANF), connective tissue growth factor
(CTGF), TNF, interleukin

(lL)-1~,

IL-6, and IL-10were quantified by real-time PCR

using Fast SYBR® Green (Applied Biosystems). GAPDH mRNA expression was
used to normalize the data. Expression level of each targeted gene was
normalized by subtracting the corresponding GAPDH threshold cycle (CT) values
using the

~~CT

comparative method [93]. The primer pairs used are detailed in

Table 1.
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Table 1. Primers Used for Real-Time PCR

tv

01

Gene

Forward Primer

Reverse Primer

ANF

5'-CCTGTGTACAGTGCGGTGTC -3'

5'-AAGCTGTTGCAGCCTAGTCC -3'

CTGF

5'-AAGACACATTTGGCCCAGAC -$

5'-TT ACGCCATGTCTCCGT ACA-$

TNF

5'-ACGGCATGGATCTCAAAGAC -3'

5' -TGGAAGACTCCTCCCAGGT A-3'

IL-1B

5'-TCATTGTGGCTGTGGAGAAG ~'

5'-AGGCCACAGGTATTTTGTCG-3'

L-S

5'-GTTCTCTGGGAAATCGTGGA -3'

5'-GGAAATTGGGGTAGGAAGGA -3'

IL-10

5'-TGCTATGCTGCCTGCTCTTA _3'

5'·TCATTTCCGATAAGGCTTGG-$

GAPDH

5'-TGATGACATCAAGAAGGTGGTGAAG- 3'

5' -TCCTGGAGGCCATGTGGGCCAT-3'

A NF, atrial natri...-etic factor; CTG F, oomective tissue growth factor; TNF, UTlor necrosis factor-a;
IL, iltedetltin; GAPOH, glyceraldehydes phosphate dehydrogenase.

Tissue harvest. Following the final echocardiographic or hemodynamic study,
mice were given additional anesthesia with sodium pentobarbital (50 mg/kg IP),
diastolic-arrested with LV. KCL, and the heart was rapidly excised and rinsed in
ice-cold physiological saline. Ventricles and atria were dissected and weighed
separately. Liver, kidneys, spleen, and lungs were dissected and weighed as
well. Lungs were subsequently dried for 48 hrs at 60°C and weighed to yield
wet-dry ratios. Tibia length was taken for tissue weight normalization. A shortaxis section of the LV was formalin fixed for 16 h, dehydrated in ethanol, and
paraffin-embedded for subsequent histological studies. The remaining LV tissue
was separated into infarcted (scar) and non-infarcted regions, snap-frozen in
liquid nitrogen, and stored at -80°C for biochemical and molecular studies. Noninfarcted tissue was used for molecular analyses.

Flow Cvtometric Analysis of Peripheral Blood.

Approximately 100 uL of

peripheral blood was collected via facial vein technique [94] into BO Microtainer
tubes with EOTA (BO Biosciences, 365973). Blood was then lysed with 2 mL
RBC lysis buffer (eBiosciences, 00-4333-57) for 5 min on ice in a 15 mL conical
centrifuge tube followed by PBS quenching via addition of 10 mL cold PBS.
Cells were then centrifuged at 380g for 10 min/4°C and the supernatant was
discarded.

The pellet was resuspended in 400 uL of ice cold flow cytometry

staining buffer (eBioscience, 00-4222-57) and divided into two plastic flow
cytometry tubes yielding two 200 uL tubes for each animal.

Each tube was

subsequently incubated for 30 min on ice with fluorescently labeled cell surface
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antibodies (0.6ug/106 cells) for the Monocyte Cell Panel: F4/80-Pacific Blue,
CD11 b-PE.

Cells were then centrifuged at 380g for 1Omin/4 °C, and the pellet

was resuspended in 400 uL of ice cold PBS.

Samples were immediately

analyzed on a BD LSRII flow cytometer equipped with 405, 488, and 633nm
lasers and appropriate filter sets. A non-debris gate was established on a FSC
vs SSC gate and positivity for respective surface markers was determined from
subsequent histograms.
antibodies

were

analyzed

fluorescence threshold.
v.7.6.

Unstained and f1uorescently labeled respective Ig
to

determine

negative

populations

and

set

Final analysis was performed using FlowJo software

Activated monocytes were taken to be F4/80+CD11 b+.

Blood was

analyzed on all animals at baseline 1 day, 1 week, and 4 weeks post-infarction.

Statistical analysis. Comparisons of experimental data were made using a
repeated measures analysis of variance (ANOVA). Animal survival was
evaluated by Kaplan-Meier analysis, and comparisons of survival between
groups at specific time points was made by both Cox regression and long-rank
statistics. Statistical significance was accepted at p < 0.05.
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RESULTS

Chimeric Mice Exhibit Similar Baseline Cardiac Phenotypes

One of the initial concerns during the planning of this study was whether the
generation of the chimeric model would in and of itself alter cardiac structure
and/or function differentially between the three experimental groups. It therefore
was necessary to determine if chimeric mice, had baseline differences in their
cardiac phenotype. The concern was warranted due to the use of lethal doses of
radiation during the process of generating the chimeric model and reconstitution
of the bone marrow compartment with genetically modified cells. The baseline
cardiac phenotype, in terms of myocardial volumes and cardiac performance
determined by ejection fraction (EF) for the TNF R1-/- chimera mice thus far
referred to as R1-/-c and the TNF R2-/- chimera group hence forth, R2-/-c, was
not different from the control C56BU6 chimera, WTc.

On the following page,

representative long axis echocardiograms of the baseline studies are shown on
the left and graphical demonstration of volumetric data, end diastolic volume
(EDV), end systolic volume (ESV) and EF demonstrated on the right (Figure 5).
The overall volumes are smaller universally then expected for naive mice. We
believed that this was likely due to the radiation administered. The important
fact, however, was that the animals demonstrated no difference amongst the
groups at baseline.
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Figure 5. A : Representative long-axis echocardiographs show no change in left
ventricular size between WTc,TNFR1-1--c and TNFR2-/-c groups. Quantitative
group data confirm this find ing. B. Graphical representation of group echo data
showing no baseline changes in EDV, ESV, or EF.
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Proof of Concept: Monocytes/ Macrophages are Activated in the Peripheral
Blood in Chronic Heart Failure

As the central theme of our hypothesis was that activated inflammatory cells play
a detrimental and modifiable role in chronic HF, it was of paramount importance
to prove monocytes were activated in a sustained manner in the peripheral blood
in response to ischemic injury. In order to determine the level of monocyte
activation in HF, WT mice where subjected to permanent coronary ligation. Flow
cytometric analysis was performed to evaluate blood monocyte activation.
Activated monocytes were identified as CD11 band F4/80 dual positive cells. A
marked increase in this cell population was noted at 4 weeks post ligation (3.59
1.1 vs. 9.78

±

± 0.4 % gate), indicating a sustained inflammatory reaction

generated by myocardial injury. To insure that this same increase in
mononuclear inflammatory cells also occurred in TNFR null animals, TNFR1-/and TNFR2-/- mice were subjected to the same protocol. Flow cytometric
analysis of their peripheral blood for dual CD 11 band F4/80 positive cells yielded
a similar finding with evidence of a pro-inflammatory milieu 4 weeks post injury in
TNFR1-/- (4.17

±. 0.76 vs. 7.74 ± 0.87 % gate) and TNFR2-/- (4.15 ± 0.96 vs.

11.0 ± 1.55 % gate) (Figure 6).
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Figure 6. A: Representative flow cytometric analysis of actJvated blood monocytes at baseline
on the left and at four weeks post ligation on the righL B: Graphical representation of each group
at baseline and four weeks post Infarction

Proof of Concept: Activated Macrophages Infiltrate the Failing Myocardium
Producing Inflammatory Cytokines

We next performed cardiac tissue analysis looking for infiltration of macrophages
into chronically infarcted myocardium.

Activated mononuclear cells in the

periphery must infiltrate the infarcted myocardium in order to produce significant
myocardial damage and dysfunction, given the typical juxtacrine effects of
inflammatory cells.

We first used green fluorescent protein (GFP) generated

chimeric mice (GFPc), Le. somatic wild type and GFP positive bone marrow, to
determine if inflammatory cell infiltration into the infarcted myocardium occurred.
GFPc animals were subjected to permanent coronary ligation and followed for
four weeks. They were then sacrificed and the myocardial tissue examined with
fluorescent microscopy. Interestingly, we found GFP positive cells in and around
the area of myocardial injury, since these animals were GFP chimeras, the
fluorescent cells could only have been generated in the bone marrow and were
therefore, inflammatory cells. We next sought to determine whether the infiltrating
cells were in fact activated while in the myocardial tissue. To do this we used
C57BL6 WT mice as well as TNFR1 and TNFR2 whole body knockouts. These

animals were subjected to either sham operation or coronary ligation.

Four

weeks post ligation these animals were sacrificed and the myocardial tissue was
immunostained with MOMA-2, a marker of macrophage activation, and anti-TNF
antibody. Fluorescent microscopy was performed. MOMA-2 analysis revealed
enhanced macrophage infiltration in the failing heart, especially in the border
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zone myocardium. Importantly, MOMA-2 positivity was not significantly increased
compared to sham in TNFR1 knockout HF hearts (NS) but exaggerated in
TNFR2 knockout HF hearts compared to sham animals (p<O.05) (Figure 7).
Moreover, dual immunofluorescent staining for MOMA-2 and TNF in failing
hearts, revealed strong macrophage TNF expression, further indicative of cell
activation. (Figure 7)

These results confirmed

infiltration of activated

inflammatory cells into the failing heart, and suggested that these cells
compromised a significant source of inflammatory cytokines.
significance of this was determined with further experimentation.
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The functional

MOMA-2 Staining
• p < 0.05

WISham

Figure 7. A: In GFP chimeric mice , GFP positive cells infiltrate the infarcted
myocardium implying migration from bone marrow. B: Immunohistochemical
identification of activated macrophages using anti-MOMA-2 in sham (top) and in
failing mouse hearts (bottom). C: Quantification of MOMA-2 staining in WT,
TNFR1-/- and R2-/- hearts. Activated macrophages were increased in WT and
TNFR2-/- HF hearts (*p < 0.05 vs sham), but not in TNFR1-/- HF. Also, TNFR2-/HF had significantly more activated macrophages as compared to TNFR1-/- HF
(p=0.012). D: On the left panel, WT HF sections were stained with either antiMOMA-2 for activated macrophages , anti-TNF (green, FITC-Iabeled secondary
antibody), and DAPI to label nuclei (blue) , and imaged with confocal microscopy
As seen in the overlay images, there was co-localization of TNF with macrophages.
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Selective Loss of Either TNF Receptor in Inflammatory Cells Yields a ProSurvival Benefit

There was no difference observed in the survival between the three chimeric
0NTc, R1-/-c, and R2-/-c) sham groups (p=NS). However, when compared to
WTc sham, WTc HF animals showed an approximately 40% mortality. This is in
line with previously observed mortality rates for C57BLl6 permanent coronary
ligation models in both our laboratory and others [63,92]. Interestingly, in postinfarction HF, we found that ablation of either TNF receptor in the inflammatory
cell compartment improved survival significantly over WTc HF animals (80% vs.
60%). This can be seen in the Kaplan-Meier survival curve shown below (Figure
8). This phenomenon of increased survival with ablation of either of the TNF
receptors was also previously observed in somatic TNFR1 and R2 null mice [63].

36

Figure 8: Kaplan-Meier survival curves from WTc, R1-/-c, and
R2-/-c mice after coronary ligation (HF) or sham operation.
Sham animals demonstrated significant improved survival over
their HF counterparts. Interestingly, both R1-/-c and R2-/-c HF
groups showed improved survival when compared to the WTc
HF group.

The Initial Level of Injury was Equivalent Between all HF Study Groups and
not a Reason for the Difference in Survival Noted Between the TNF
Receptor Knockout Chimeras and WT Chimeras

To ensure no significant difference was present in the initial myocardial injury that
might explain this difference in survival in the HF groups, infarct area as a
percent of total LV area at 4 weeks was measured for each animal. This data
demonstrated that there was no difference in the infarction area observed in the
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3 groups (p=NS) indicating that the survival benefit observed was not from
differences in initial injury. (Figure 9)

Figure 9: Quantification of infarction area as percent of LV
area demonstrating equivalent injury in each of the HF
groups.
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LV Remodeling and Dilatation post Infarction is Attenuated by the Selective
Loss of TNFR1 in the Inflammatory Compartment, while Similar Loss of
TNFR2 Demonstrates no such Benefit

Four weeks following coronary ligation, LV tissue sections were obtained as
described in the methods section. Demonstrated below are representative LV
short axis tissue sections and M-mode echocardiograms corresponding to WTc
sham and WTc HF, again demonstrating that permanent coronary ligation
resulted in a substantial level of myocardial injury and LV dilatation.

When

comparing representative R1-/-c HF images, the magnitude of these changes
was attenuated. An obvious decrease in LV dilatation is seen in the gross cross
section and improved myocardial performance noted on M-mode. The R2-/-c HF
example shows LV dilatation and systolic dysfunction similar to WTc HF. The
R1-1-c and R2-/-c shams are phenotypically similar to the WTc sham, again
demonstrating no significant differences in uninjured myocardium. (Figure 10)
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Figure 10. A: Representative left ventricular short-ax-s cross sections. While hearts from all three HF groups were
significantly increased in size over sham , gross changes between R2-/-c and WTc HF animals were Significantly greater
when compared to R1-/-c HF. B: Representative M-mode echocardiograms. As with gross pathology, no apparent
differences were observed between the WTc and R2-/-c HF groups, however significantly improved function was noted
in the R1-/-c HF animals. R1-/-c and R2-/-c shams are not shown for simplicity but were not different from WTc shams.

In vivo Measurements of Chamber Dilitation and Performance Demonstrate
Improved LV Remodeling and Myocardial Performance with the Loss of
TNFR1 in Inflammatory Cells

The observation of exaggerated lV chamber dilatation in WTc HF and R2-/-c HF
hearts

compared

with

R1-1-c

hearts

HF

were

confirmed

by

group

echocardiographic data. lV size was indexed by end diastolic and end systolic
volume (EDV and ESV), and systolic function was indexed by lV EF. EDVand
ESV were significantly increased in each of the HF groups when compared to
respective sham animals. The degree of chamber dilatation, as measured by
EDV, however, was attenuated in R1-/-c HF when compared with either WTc HF
(96.7 ±. 13.7 vs. 65.7 ±. 13.8 IlL) or R2-/-c HF (111.1 ± 28.5 vs. 65.7 ±. 13.8 Ill).
A similar effect was observed for ESV comparing WTc HF to R1-/-c HF (72.1 :!:.
14.6 vs. 37.0 :!:. 9.7 )ll) and R1-1-c HF and R2-/-c HF groups (37.0 :!:. 9.7 vs. 85.6

:!:. 22.9 IlL) (Figure 11). The R1-1-c HF group also demonstrated a much higher
EF as compared to either WTc HF (42.9
animals (42.9 :!:. 4.2 vs. 22.3

.±. 4.2

vs. 25.5 :!:. 7.5 %) or R2-/-c HF

.±. 4.6 %) (Figure 11). No significant difference was

observed in either lV size or ejection fraction between R2-/-c and WTc HF
(p=NS). (Figure 11)
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Figure 11: Quantification of echocardiographic parameters of end diastolic volume (EDV).
end systolic volume (ESV). and ejection fraction (EF). All HF groups had significantly
increased volumes both EDV and ESV and reduced EF compared to sham indicative of
LV dilatation and impaired systolic function . however the R1-/-c HF group demonstrated less
change from the sham groups In all three parameters compared to the WTc and R2-/-c HF.
R1-/-c and R2-/-c sham groups are not shown for simplicity but are not different from WTc sham

Mice with Deletion of TNFR1 in Inflammatory Cells Demonstrated Less
Pulmonary and Systemic Congestion

and

Myocardial

Mass

in

HF

Consistent with Improved HF Physiology

Following animal sacrifice, analysis of tissue weights was performed as
described in the methods section. An increase in LV mass and increased lung
and liver weights consistent with LV hypertrophy and increased lung and liver
water were seen in all HF groups compared to sham (p<O.05). In accordance
with the echocardiography data showing less LV remodeling and improved
performance in R 1-/-c failing hearts (Figure 11) there was a decrease in heart
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size normalized to tibia length in R1-/-c HF when compared with either WTc HF
(4.79 ±. 0.64 vs. 6.39 ±. 0.44 mg/mm) or R2-/-c HF (4.79

± 0.64 vs. 6.85 ±. 1.05

mg/mm) groups. When analyzing LV mass individually, again normalized to tibial
length, a similar trend was noted upon comparing R1-/-c HF with either WTc HF
(3.14

± 0.20 vs. 3.91 ± 0.53 mg/mm) or R2-/-c HF groups (3.14 ± 0.20 vs. 4.07 ±.

0.27 mg/mm).

Additionally, R1-/-c HF had reduced lung and liver weights,

compared with either WTc HF or

R2-/~

HF (p<0.05). R2 HF and WTc HF

demonstrated no significant differences in heart, LV, lung or liver weight (p=NS)
(Figure

12).

Pulmonary

and

systemic

congestion,

hallmarks

of the

pathophysiology of HF are indexed here by lung and liver weights mentioned
previously. The R2-/-c and WTc HF groups had significantly higher lung and liver
weights then the R1-/-c HF mice, demonstrating an attenuated HF physiology in
the R1-/-c mice.
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Myocyte Area and

Atrial Natuiretic Factor (ANF) Expression were

Significantly Attenuated in R1-/-c HF Mice Compared to Either R2-/-c or
WTc HF Mice

Myocyte area was assessed using wheat germ agglutin 0NGA) staining and
representative images are shown in Figure 13. In each HF group there was an
increase in myocyte size compared to sham, as is expected with a significant
level of injury subsequently resulting in pathological hypertrophy. However, in
the R1-1-c HF group this increase in size was attenuated when compared to
either WTc HF (255.64

± 64.98

vs. 325

± 73.45

11m2) or R2-/-c HF (255.64

±

64.98 vs. 331.89 ± 71.87 11m2). This pattern was further supported by evaluation
expression of ANF, a protein marker of myocyte hypertrophy. ANF expression
was significantly increased in WTc HF hearts and R2-/-c HF hearts over sham
(WTc HF 5.14

± 1.34

fold increase; and R2-1-c HF 4.26

± 2.04

fold increase),

however, no significant increase was noted in the R1-/-c HF hearts compared to
sham (1.19 ± 0.9 fold change) consistent with the decrease in myocyte
hypertrophy observed with histological analysis (Figure 14).
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WTc

Rl-/-c

R2-/-c

Figure 13: Representative images of wheat germ agglutin staining (WGA).
Shown are WTc, R1-/-c, and R2-/-c sham and HF. All HF groups demonstarted
Myocyte hypertrophy compared to the sham groups. However, the R1 -/-c HF
group had significantly less hypertrophy compared to either the WTc or
R2-/-c HF animals.
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Figure 14. A: Graphical quantification of myocyte area as measured by wheat germ agglutin syaining (WGA).
All HF groups demonstrated significantly increased myocyte area when compared to their corresponding
shams. However, the R1-J-c HF group had Significantly less hypertrophy compared to the other two HF groups.
B: Quantified RT-PCR of atrial naturetic factor (ANF), confirming the hypertrophy data, the level of ANF in R1-J-c
HF hearts was significantly less then either the WTc or R2-J-c HF groups.

Decreased Total Fibrotic Area Seen in R1 HF Group Compared to Both R2
HF and WTc HF groups

Total LV fibrorotic area was assed using Trichrome staining. Shown in Figure 15
are

representative

histomicrographs

of

non-infarcted,

and

remodeled

myocardium, and the corresponding group quantitation of fibrotic area (Figure
15). There was a significant increase in collagen deposition in all three HF
groups when compared to their respective sham groups (p<0.05). However, this
was most pronounced in the WTc and R2-/-c, and was less in R1-1-c HF
compared to either WTc HF (5.48 ±. 2.26 vs. 16.10 ±. 8.16 % area) and R2-/-c HF
(5.48 ±. 2.26 vs. 21.92 ±. 10.81 % area). (Figure 15)
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Figure 15. A: Representative Trichrome staining of sham and HF hearts. Significant levels
of fibrosis (blue) are seen In all HF groups compared to sham. B: Quantification of total myocardial
fibrotic area demonstrates significant increased fibrosis in all HF groups compared to sham. however.
R1-/-c HF had significantly less fibrosis following infarction then either WTc or R2-/-c HF groups.

Attenuated Fibrosis was Observed in the R1-1-c HF Hearts in the Region
Immediately Adjacent to the Infarction as well as Areas Remote to the
Injury

Trichrome analysis to delineate fibrotic burden of the border zone, the area
immediately adjacent to the infarcted myocardium, and the remote zone, the area
of LV uninvolved by infarction , demonstrated a similar pattern with regard to total
fibrotic area. Specifically, in the border zone significantly increased fibrosis was
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noted in all HF groups as compared with sham (p<0.05). However, there was
significantly less borderzone fibrosis noted in R1-/-c HF compared to either
R2-1-c HF orWTc HF (5.48 ±.2.26 vs. 16.10 ±.8.16 vs. 21.92 ± 10.81 % area,
respectively).

In the remote zone, no significant differences in fibrosis were

noted between sham and R1-/-c HF (p=NS). The remaining HF groups, R2-/-c
HF and WTc HF, both demonstrated increased fibrosis compared to sham.

However, no significant differences were noted between R1-1-c HF and WTc HF
(p=NS). There was however a significant increase in fibrosis in the remote zone
in the R2-/-c HF group compared to either WTc HF (4.78 ±. 2.02 vs. 2.6 ±. 1.62 %
area) and R1-/-c HF (4.78 ± 2.02 vs. 1.80 ± 1.34 % area) (Figure 16).
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Figure 16. A: Representative Trichrome staining of sham and HF hearts. Significant levels of fibrosis
(blue) are seen in all HF groups compared to sham. B: Quantification of myocardia border zonel
Fibrosis. All HF groups had significantly increased border zone fibrosis. R1-/-c HF animals had
significantly less fibrosis than either WTc or R2-/-c HF. C: The Remote zone. demonstrated
significantly Increased fibrosis in all HF groups compared to sham; however. R1-/-c HF had
significantly less fibrosis following infarction than R2-/-c HF.
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Myocardial Expression of Pro-Fibrotic Connective Tissue Growth Factor
(CTGF) Parallels the Changes in LV Fibrosis Post Infarction

RT-PCR was used to measure myocardial expression of connective tissue
growth factor (CTGF) a pro-fibrotic protein.

The pattern of post infarction LV

fibrosis demonstrated in WTc, R1-/-c, and R2-/-c HF groups discussed previously
was supported by analysis of CTGF gene expression, which exhibited reponses
analogous to the change in tissue fibrosis.

Specifically, all HF groups

demonstrated significantly increased cardiac expression of CTGF compared to
sham (p<0.05).

Interestingly, R1-/-c HF hearts showed a significant fold

decrease in CTGF expression compared to either WTc HF (1.66 ± 0.50 vs. 2.28
.:!:. 0.62 fold increase) and R2-/-c HF hearts (1.66

increase) (Figure 17).
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±. 0.50 vs. 2.61

.:!:. 1.22 fold

Figure 17. A: Representative Trichrome staining of sham and Hf hearts
in the WTc, R1 -I-c, and R2-/-c groups. B: Quantified RTPCR values of myocardial
expression of connective tissue growth factor (CTGF). CTGF was increased
in all HF groups over their respective shams. Compared to R2-/-c HF and WTc
HF, R1-I-c HF had significantly lower levels of CTGF expression.
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No Significant Difference was noted in Activated Peripheral Monocytes
(F4/80+/ CD11b+) Amongst the Three Study Groups in NaIve Animals

Flow cytometric analysis was performed on peripheral blood samples obtain from
naive mice in each of the three study groups, WTc, R1-/-c, and R2-/-c. Activated
monocytes were identified as dual positive F4/80 and CD11 b cells.

No

significant difference was noted between any of the three groups at baseline
(p=NS). (Figure 18)

Figure 18: Activated momocytes as defined by dual positivity of
F4/80 and CD11b by flow cytometry in the peripheral blood of
Na"lve WTc, R1 -/-c, and R2-/-c mice. No significant difference
was noted between any of the groups.
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An Exaggerated Level of Activated Monocytes (F4/80+1 CD11b+) was
Demonstrated by Flow Cytometry in the Peripheral Blood of R2-1-c HF Mice
in Response to Myocardial Injury

Activated monocytes, identified as cells dual positive for F4/80 and CD11 b by
flow cytometric analysis, were significantly increase in all HF groups compared to
their respective baselines and shams at all time points observed, with the
exception of R1-/-c HF at 1 week post infarction. Interestingly the R2-/-c HF
group demonstrated significantly higher levels of circulating activated monocytes
compared to WTc HF at 1 day (15.32 ±. 4.41 vs. 12.10 ±. 1.24 % gate) and 4
weeks (12.06 ±. 1.73 vs. 5.90 ±. 0.75 % gate) post infarction, and at all observed
timepoints compared to R1-/-c HF 1 day (15.32 ±.4.41 vs. 8.19 ±3.08 % gate), 1
week (10.40

±. 1.67 vs.

5.81 ±2.27 % gate), and 4 weeks (12.06 ± 1.73 vs. 6.68

± 0.94 % gate). This supports an important role for TNFR1 in the activation of
monocytes in HF (Figure 19).
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Figure 19: Quantified values of activated monocytes, identified as dual positive cells
(F4/80 and CD11 b) by flow cytometry, in the peripheral blood of WTc sham, WTc
HF, R1-I-c HF, and R2-/-c HF. R1-/-c and R2-/-c shams not shown, but were not different
from WTc sham. R2-/-c HF demonstrated an exaggerated increase in activated
monocytes compared to the WTc and R1-/-c HF groups at all time points post infarction
with the exception of WTc HF at 1 week post infarction.
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Loss of Inflammatory Cell TNFR1 Attenuates Myocardial Inflammation in
the Failing Heart

RT-PCR was used to measure cardiac expression of the pro-inflammatory TNFa,
IL-1~,

and IL-6, as well as the anti-inflammatory cytokine IL-10. TNFa expression

was significantly increased in WTc HF over sham (1.64

± 0.33 fold increase).

Interestingly, there was no TNFa upregulation, as compared to sham, in either
R1-1~

HF (0.42

± 1.95 fold change) or R2-/-c HF (1.02 ± 0.75 fold change)

(Figure 20). These findings indicated that both TNFRs need to be functional in
the inflammatory compartment to induce TNF expression in the failing
myocardium. R1-/-c HF also showed non-significant fold changes in the levels of
IL-1~

(0.53 ± 1.88 fold change) and IL-6 (1.50 ± 1.2 fold change) compared to

the R1-/-c sham. The absolute fold change in
significantly lower than in the R2-/-c HF (0.53
and WTc HF (0.53

± 1.88 vs.

1.86

± 0.55

IL-1~

in the R1-/-c HF group was

± 1.88 vs. 1.72 ± 1.31 fold change)

fold change) groups. This indicates

less myocardial inflammation in the R1-1-c HF hearts as compared to both WTc
and R2-/-c HF, indicating that TNFR1 signaling in inflammatory cells is required
for myocardial cytokine expression.

The R2-/-c HF group demonstrated a

predictable and significant increase in both
IL-6 (2.13

IL-1~

(1.72

± 1.31 fold increase) and

± 1.24 fold increase) gene expression relative to sham. The WTc HF

hearts exhibited similar

IL-1~

and IL-6 expression as compared with R2-/-c HF

hearts. Myocardial expression of IL-10, a well-established anti-inflammatory
cytokine, was increased in the R1-/-c HF group compared to sham (1.57

57

± 0.80

fold increase), but not in WTc or R2-/-c HF, consistent with the observed blunted
inflammatory response in R1-/- chimeras (Figure 20).
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Figure 20. A: RTPCR quantified myoycardial expression of tumor necrosis factor alpha (TN F), B: interleukin (IL)
6 (IL-6), C: IL-10, and 0: IL-1B.

Conclusions

The data in this chapter demonstrated that selective loss of TNFR1 in
inflammatory cells profoundly influences post-infarction cardiac remodeling and
protects the failing myocardium from many of the deleterious processes that
define the pathology of HF. Specifically, deletion of TNFR1 in the inflammatory
compartment alleviated contractile dysfunction and chamber dilatation, LV and
myocyte hypertrophy, interstitial fibrosis, peripheral monocyte activation, and
myocardial inflammation with significant reductions in TNF, IL-6, and

IL-1~

expression and increases in IL-10 expression.

Conversely, selective loss of TNFR2 in inflammatory cells did not significantly
influence post-infarction cardiac remodeling in that the LV performance and
dimensions measured by echocardiography were not significantly different from
the WTc HF group.

It did, however, modestly augment interstitial fibrosis,

compared to WTc, and reduce TNF expression.

Nonetheless loss of either TNFR1 or TNFR2 in inflammatory cells improved
survival over WTc HF mice. This is an interesting finding in that, even though
loss of TNFR2 did not significantly change the phenotypic picture of chronic HF
with regards to LV function, inflammatory cytokine production (with the exception
of TNFa), and myocyte hypertrophy, it offered a survival benefit.

This is even

more interesting in that it correlated with previously reported data [63] indicating
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a similar survival benefit in TNFR -/- HF mice despite seemingly unimproved
myocardial dysfunction post coronary ligation.

Possible explanations for this

include scar stabilization, decreased electrical abnormalities, and decreased
systemic effects of HF, all likely the result of more complex intercellular and
intracellular TNF related signaling mechanisms then are currently appreciated.
Myocardial rupture is a prominent cause of death early in the time course of post
infarction remodeling in mice. While a slight increase in myocardial fibrosis was
noted in the R2-/-c HF hearts, we can not fully determine the level of scar
stability, i.e. its resistance to mechanical forces.

Improved tensile strength

would certainly better resist myocardial rupture. Sudden cardiac death (SeD), a
product of malignant ventricular arrhythmias, is common in the sub acute
infarction period. While this is difficult to monitor in an animal model it is likely
this represents, as it does in humans, a significant cause of mortality.
Differences in scar formation and fibrosis are well known to influence these
electrical abnormalities. While differences in remodeling were evident in the R1/-c HF mice, it was less so with the R2-/-c HF animals.

More sophisticated

analysis of the fibrotic areas and electrical behavior of these animals would be
needed to determine the likelihood of this explanation.

Likewise, worsening

systemic HF physiology can contribute to mortality. The observed requirement of
both TNF receptors to induce myocardial TNFa production could playa role in
improved HF physiology from the R2-/-c group, although from the analysis of liver
and lung weights, along with echocardiographic data, it appears this is unlikely to
be the case.
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It is apparent from this work that modulation of global inflammatory cell function
induces significant localized changes in cardiac remodeling, and that TNF
receptor signaling plays an important role in these effects. Inflammatory celllocalized TNFR1 exacerbates post-infarction LV remodeling and is required for
the genesis of a pro-inflammatory state in failing myocardium. Inflammatory celllocalized TNFR2 imparts modest beneficial anti-fibrotic effects in the remodeling
heart.

Independent of the myocyte-specific effects of TNF, TNF-dependent

inflammatory cell responses are critical for the progression of post-infarction
remodeling in HF.
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CHAPTER V

AIM #2: TUMOR NECROSIS FACTOR SIGNALING IN MACROPHAGES
MODULATES JUXTACRINE MACROPHAGE-MYOCYTE INTERACTIONS IN
HEART FAILURE

BRIEF PREVIEW

Background: While our previous findings indicated that selective ablation of
bone marrow TNF Receptor 1 is beneficial, and that ablation of TNF Receptor 2
yields modest detrimental effects in

HF, the exact underlying

cellular

mechanisms of these effects are still unknown. In this aim, we will discuss
potential mechanisms whereby infiltrating macrophages can interact with
myocytes. To date it is unknown whether induction of myocardial dysfunction is a
paracrine, cytokine mediated event or if actual cell-ta-cell interaction is
necessary; therefore, we will determine both paracrine and juxtacrine interactions
between the macrophage and cardiomyocyte.

Methods: Heart failure was induced by permanent coronary artery ligation in
C57BLl6, TNFR1-1-, and TNFR2-/- mice (Jackson Labs) as described previously.
The HF mice were then treated with an intraperitoneal injection of the
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macrophage attractant thioglycollate. Five days later, peritoneal macrophages
were collected via peritoneal lavage and placed in co-culture with freshly isolated
na"ive cardiomyocytes. Macrophages isolated from sham operated animals
served as the negative control, whereas, macrophages isolated from sham
animals and artificially stimulated with lipopolysaccharide (LPS) served as the
positive control. Cardiomyocyte contractile function was measured via videoedge detection (lonOptix) during digital field stimulation (1 Hz) under various
conditions: 1) baseline cardiomyocyte contraction, 2) contraction following
addition, but no attachment, of isolated macrophages, and 3) contraction
following addition and attachment of macrophage and cardiomyocyte for 15
minutes. In separate experiments, cardiomyocytes were pre-loaded with the
general marker of oxidant stress 5-(and-6)-carboxy-2', 7' -dichlorofluorescein
diacetate (DCFDA), a fluorescent indicator of ROS levels, and subjected to the
same experimental conditions.

RESULTS: Upon physical attachment of wild type LPS-stimulated macrophages,

cardiomyocytes exhibited significantly depressed sarcomeric shortening (4.8 ±
1.9 vs. 10.5 ± 2.1 % shortening). This was determined to be a solely juxtacrine
effect since addition of stimulated

macrophages,

without cardiomyocyte

attachment, had no significant impact on sarcomeric shortening (9.26 ± 3.54 vs.
10.5 ± 2.1 % shortening). This effect was mirrored in macrophages isolated from
HF animals without pre-stimulation with LPS (4.5

± 2.8 vs. 10.5 ± 2.1 %

shortening), implying that macrophages are sufficiently pathologically activated in
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HF for the induction of myocyte dysfunction. Interestingly, while attachment of
-,/-

macrophages isolated from TNFR1

HF animals still induced cardiomyocyte

contractile depression as compared to wild type controls, the resultant
depression was significantly altered as compared with WT HF macrophages
(7.06 ± 1.44 vs. 4.5 ± 2.8 % shortening). Conversely, TNFR2-1- HF macrophage
augmented myocyte contractile dysfunction upon cell-to-cell interaction (2.80
0.19 vs. 4.5

±. 2.8

% shortening).

±.

Cell contact between macro phages and

cardiomyocytes pre-loaded with the oxidant stress indicator DCF-DA, revealed
30 fold increased myocyte oxidant stress 15 minutes following attachment of WT
HF macrophages, and abrogation of this response upon attachment of TNFR1-'/HF

macrophages.

Conversley,

TNFR2-'/-

HF

macrophage

attachment

significantly increased myocyte oxidant stress as compared to WT HF
macrophages.

CONCLUSIONS: We have provided mechanistic insight into the potential role of

tissue macrophages in the production of contractile dysfunction and the first
known report that the TNF receptors have divergent roles not only in in vitro
single cell line culture models, but in cell-to-cell macrophage/cardiomyocyte
interaction and function. In the infarcted animal, peripheral blood macrophages
were pathologically activated and infiltrated the myocardium. Our previous data
imply that many of the effects of these infiltrating cells may be most pronounced
in the infarct border zone (Le., changes in extracellular matrix components) and
may, at least in part, be dependent on the interplay of various inflammatory
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mediators (iNOS, TNF, etc.). The effects of direct interaction between infiltrating
macrophages and cardiomyocytes, and the role of TNFR-specific responses, are
unknown. Data from this Aim indicates that direct, juxtacrine interactions between
activated infiltrating macrophages are sufficient to induce oxidant stress and
contractile depression in cardiomyocytes. This process is further influenced by
the differential roles of immune cell TNF receptors. Moreover, our data confirm
previous studies, in that paracrine (as opposed to juxtacrine) interactions
between macrophages and cardiomyocytes were not sufficient to cause
contractile dysfunction in the in vitro, co-culture setting.
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INTRODUCTION

While recent evidence has provided some mechanistic insight into the role of
inflammation in the heart failure, much has been left undetermined. The role of
the "foundation cytokine" TNF in HF remains unclear. Specifically, while much is
known regarding the divergent pathways of generalized TNF receptor 1 and 2
signaling, the possibly critical contribution of cellular source has not been
determined until this study. Aim 1 of this project provides the first evidence that
the source of TNF receptor is critical for beneficial or detrimental function (Le.
whereas inflammatory cell-specific TNFR1 ablation is beneficial to pathologic
remodeling, TNFR2 ablation is modestly detrimental); however, this only further
warrants studies into the cellular interactions between infiltrating inflammatory
cells and the injured myocardium, specifically the cardiomyocyte itself.
Therefore, we extended our studies in Aim 2 to more clearly delineate the
underlying mechanisms through which these beneficial or detrimental processes
may occur.

While Aim 1 provides insights into the in vivo roles of the inflammatory cell TNF
signaling in heart failure [63, 95], it remains unknown whether these effects are
secondary to changes in the microenvironment, changes in the surrounding and
supporting cells in the ischemic areas, or alterations in direct interactions
between cardiomyocytes and infiltrating cells.

Furthermore, if interactions

between myocytes and inflammatory cells are a critical component (as we
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hypothesize), is this effect controlled by the macrophage or other infiltrating bone
marrow cells? In this Aim we will attempt to uncover answers to these and other
questions.

In addition to cellular source, the downstream effects on cardiomyocyte function
are of critical importance as well. Are the observed effects secondary to changes
within the cardiomyocyte or localized solely to the extracellular matrix and
environment?

If localized to the cardiomyocyte one suspect process involves

myocardial oxidative stress. Myocardial generation of oxidative stress is a well
known effect of the heart failure state [96] and is a known cause of a myriad of
pathologic changes in failing myocardium including contractile dysfunction via
disruption of contractile proteins [97].

However, the exact mechanism of this

oxidant increase and the subsequent changes induced remain elusive. While we
and others have suggested that infiltrating inflammatory cells in myocardium may
contribute to oxidant stress-induced cardiac dysfunction, to-date only one paper
hints at the possible role of the physical interaction of these cell types in the
generation of oxidative stress [89]. In this elegant study, it was shown in an in
vitro,

cell

co-culture

model

of neutrophil-cardiomyocyte

interaction

that

neutrophils from septic animals were sufficiently activated to induce oxidant
stress and ensuing contractile dysfunction in cardiomyocytes.
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This important work is consistent with our findings of improved cardiac
-/-

remodeling and oxidant stress in the in vivo HF model with TNFR1

chimerism.

While exciting, it remains unknown whether inflammatory cells, activated in vitro,
function in the same manner as chronically activated inflammatory cells in HF.
Secondly, it is unknown whether macrophages in HF are sufficiently activated to
induce oxidant stress effects in cardiomyocytes in a manner analogous to sepsisactivated neutrophils. While these questions remain unanswered to date, it is
notable that macrophages, like neutrophils, produce the foundation cytokine TNF
in response various stimulants [98,99].

Taken together with our data that

macrophages infiltrate the myocardium and are activated during heart failure, we
hypothesize that macrophage-cardiomyocyte interaction in the failing heart is
sufficient to induce contractile dysfunction via mechanisms related to free radical
generation. We investigated this hypothesis using a cell co-culture model of
macrophage-cardiomyocyte interaction.
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MATERIALS AND METHODS

Animals. For these studies, commercially available C57BLl6 (WT), TNFRf /-,
and TNFR2-1- mice (Jackson Labs) were used. The mice were maintained in the
University of Louisville Research Resources Center. All studies were performed
in compliance with the NIH Guide for the Care and Use of Laboratory Animals
(DHHS publication No. [NIH] 86-23, Revised 1996).

Coronary ligation and experimental protocol. Permanent coronary ligation
was performed as previously described [63,92]. Anesthesia was induced in mice
with tribromoethanol (0.25 mg/g IP). After induction, the mice were intubated and
supported with a MiniVent Mouse Ventilator (Type 845, Harvard Apparatus) at
125-150 breaths/minute depending on body weight (tidal volume 6.4 !JLlg, PEEP
5-7 cm H20). Anesthesia was maintained with 1% isoflurane. Heat lamps and
heating pads were used to maintain body temperature at 3rC. Under sterile
conditions, a left thoracotomy was performed in the 4th intercostal space, the
heart was exposed, and the pericardium was opened. An 8.0 prolene ligature
was passed and tied around the proximal left coronary artery, 1 mm distal to the
left atrial appendage border. Successful occlusion was confirmed by the
production of pallor and dyskinesia in the distal myocardium. In sham animals,
the suture was passed but not tied. The chest was then closed in layers using 5.0
silk, and the mice were allowed to recover and followed for 4 weeks. The total
mice used for these studies were as follows: C57BLl6 (n = 10), TNFR1
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(n = 10),

-------
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-/-

TNFR2 (n = 10). Mice were followed for 4 weeks following operation, and were
used for macrophage harvest.

Isolation of mouse cardiomyocytes. Na'ive mice were deeply anesthetized with

pentobarbital (80 mg/kg 1M) and given heparin 10 U/g Lp. The heart was rapidly
2+

excised, and Ca

tolerant mouse ventricular myocytes were isolated by modified

Langendorff perfusion and collagenase digestion as previously described [1,3].
Briefly, the aorta was cannulated with retrograde perfusion of Tyrode buffer (in
mM: NaCI-126, KCI-4.4, MgCI -1, NaHC0 -18, Glucose-11, HEPES-4, BOM-10,
2

3

Taurine-30, Glutathione-10) followed by 12 min collagenase perfusion. Atria were
removed, and ventricular tissue was minced in collagenase mince buffer (tyrode
buffer supplemented with 0.001 % collagenase and 0_003% albumin), passed
through a 120 um mesh (Whatman) into a 1S mL conical tube, and allowed to
settle for 10 min. Supernatant was discarded, and the remaining cells were
2+

mixed with 2SuM Ca

supplemented Tyrode buffer. This process was repeated
2+

with SO,1 00,2S0, and SOOuM Ca

supplemented buffer. Finally, cells were plated

4

2

at a density of 10 rod-shaped cells/cm in serum-free supplemented OM EM
medium (with albumin 0.2%, L-carnitine 2mM, creatine SmM, taurine SmM, Lglutamine 1.3 mM, insulin 0.1 mM, triiodothyronine 0.1 nM, pyruvate 25 mM,
BOM 10 mM, and penicillin/streptomycin 0.1% (cardiomyocyte media, CMM)) at
37°C in S% CO until experimentation_ Cell viability was typically 75-80%, as
2
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assessed by trypan blue exclusion. Preparations with less than 75% viability
were discarded.

1

Isolation of peritoneal macrophages. C57BU6, TNFR1-1-, and TNFR2- - sham
or HF mice were injected ip with 3 mL Brewer thioglycollate (TG) medium
(Sigma, B2551) 5-7 days prior to harvest. Mice were euthanized with CO ,
2

followed by cervical dislocation, and cells were collected in a 50 mL conical tube
on ice via peritoneal lavage with cardiomyocyte media. Macrophages were then
isolated from lavage fluid by density gradient purification followed by washing
and resuspension in cardiac myocyte media (CMM) to a final concentration of
6

2.5x10 celis/mL. The macrophage phenotype was confirmed with FITC-Iabeled
F4/80 cell surface staining in a small aliquot. Approximately 99% of purified cells
were determined to be positive.

Co-culture experimental protocol. Isolated ventricular cardiomyocyte function
with and without macrophage attachment was determined using an lonOptix
myocyte contractility system (Milton, MA). C57BU6 cardiomyocytes were utilized
-1-

for all studies, and macrophages from C57BU6, TNFR1 ,and TNFRZI- sham or
HF mice (Jackson Labs, Bar Harbor, ME) were utilized where noted (Figure 21).
3

4

Approximately 4 hours after isolation, 10 cardiomyocytes (10 celis/mL) were
placed into the contraction system and perfused with HEPES buffer (in mM:
NaCI-137, KCI-4.9, MgSO ·7H 0-1.2, Glucose-15, HEPES-20, NaH PO -1.2,
4

2

2
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4

CaCI -1.8). Baseline sarcomeric shortening was determined during 1 Hz field
2

6

stimulation for 5 minutes. Macrophages (100 uL of 2.5x10 cells/mL) were then
introduced into the system and allowed to attach for 15 minutes. For HF
macrophage studies, cells were harvested from animals 4 weeks post-infarction,
and for LPS studies, harvested cells were treated with 5 ug/mL LPS (Sigma) for 4
hours prior to

use.

Post-attachment,

sarcomeric shortening was again

determined via 1 Hz stimulation for 5 minutes. For in vitro reactive oxygen
species production experiments, cardiomyocytes were preloaded with 2 uM 6carboxy-2',T-dichlorodihydrofluorescein

diacetate

acetoxymethyl

ester

(Molecular Probes) followed by washing to ensure no residual DCFDA in media.
Preloaded myocytes were then loaded into chambered borosilicate coverglass
systems and non-OCFDA loaded macrophages were introduced. Immediately
upon macrophage-myocyte interaction, baseline epifluorescent pictures were
started and continued every 2 minutes for 15 minutes. After 15 minutes,
brightfield images were obtained in order to quantitate number of macrophages
attached. All fluorescent studies were preformed on a Nikon Eclipse TE2000-U
microscope equipped with a mercury light source.
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Figure 21. For myocyte contraction studies (left) WT cardiomyocytes were co-cultured with WT LPS
stimulated, WT HF-derived, TNFR1 -1- HF-derived , and TNFR2-1- HF-derived and LPS stimulated
peritoneal macrophages. For free radical production studies, WT myocytes were co-cultured with WT
sham, WT HF, TNFR1 -1- HF, and TNFR2-1- HF peritoneal macrophages.

Flow Cytometric Analysis of Peripheral Blood.

Approximately 100 uL of

peripheral blood was collected via facial vein technique [94] into BO Microtainer
tubes with EOTA (BO Biosciences, 365973). Blood was then lysed with 2 mL
RBC lysis buffer (eBiosciences, 00-4333-57) for 5 min on ice in a 15 mL conical
centrifuge tube followed by PBS quenching via addition of 10 mL cold PBS.
Cells were then centrifuged at 380g for 10 min/4°C and supernatant was
discarded. The pellet was resuspended in 400 uL of ice cold flow cytometry
staining buffer (eBioscience, 00-4222-57) and divided into two plastic flow
cytometry tubes yielding two 200 uL tubes for each animal.

Each tube was

subsequently incubated for 30 min on ice with fluorescently labeled cell surface
6

antibodies (0.6ug/10 cells) for the Monocyte Cell Panel: F4/80-Pacific Blue,
C011 b-PE. Cells were then centrifuged at 380g for 1Omin/4 °C, and the pellet
was resuspended in 400 uL of ice cold PBS.

Samples were immediately

analyzed on a BO LSRII flow cytometer equipped with 405, 488, and 633nm
lasers and appropriate filter sets. A non-debris gate was established on a FSC
vs SSC gate and positivity for respective surface markers was determined from
subsequent histograms.

Unstained and fluorescently labeled respective Ig

antibodies were analyzed to determine negative populations. Final analysis was
performed using

FlowJo v.7.6.

Activated

mononcytes were taken as

F4/80+C011b+.

Statistical analysis. Comparisons of experimental data were made using a
repeated measures analysis of variance (ANOVA). Animal survival was
evaluated by Kaplan-Meier analysis, and comparisons of survival between
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groups at specific time points was made by both Cox regression and long-rank
statistics. Statistical significance was accepted at p < 0.05.
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RESULTS

Proof of Concept: Thioglycol/ate Elicited Peritoneal Macrophages are
Positive for the Macrophage Marker F4/80 and Functional and Collagenase
Disassociated Cardiomyocytes are Viable

Seven days post peritoneal injection of thioglycollate, cells harvested via
peritoneal lavage exhibited the morphology (lobed nucleus) and size (1 0-12um in
diameter) characteristics of macrophages (Figure 22A) upon light microscopy.
6

Approximately 10-15 x 10 cells were harvested from each mouse and diluted
into cardiomyocyte media. To confirm macrophage identity, immunofluorescent
staining was performed for the classical macrophage marker F4/80 (FITClabeled).

Nearly all cells were positive (99%) for the surface marker F4/80.

(Figure 228) While confirmation of macrophage phenotype was important, it was
equally critical to assess the ability of these cells to become activated upon
stimulation. To this end, we developed a protocol for macrophage stimulation
outlined in Figure 23A. One day post LPS stimulation, macrophages produced
significantly greater amounts (2.5-fold) of NOx than unstimulated macrophages.
Interestingly, these cells continued their stimulated state even 4 hours after
withdrawal of the LPS stimulus. (Figure 238) We also isolated mouse
cardiomyocytes via modified Langendorff perfusion with collagenase digestion.
The isolated cells were calcium-tolerant and of normal morphological size and
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shape (rod shape , approximately 100-120um) and behaved normally under field
stimulation. (Figure 23C)

SrightfieJd

F4I80FITC

Overlay

Figure 22. A: 5-7 days post peritoneal thioglycollate injection, peritoneal
macrophages were harvested via lavage (left image). Macrophage phenotype
was confirmed through FITC labelled F4/80 surface staining (right image). B:
Confocal microscopy confirms expected macrophage phenotype (brightfield
image at left) and surface F4/80 staining (overlay image at right).
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Figure 23: A: Isolated macrophage function was determined via the outlined
protocol. B: One day post LPS stimulation, macrophages are active and
produced 2.5-fold higher amounts of NOx. This activation continued after
withdrawal of the initial stimulus. C: Freshly isolated cardiomyocytes exhibited
normal morphological features.

LPS-Stimulated

Macrophages

Induce

Contractile

Dysfunction

Upon

Attachment to Cardiomyocytes

Upon

introduction

of

LPS-stimulated

peritoneal

macrophages

into

the

cardiomyocyte co-culture chamber, macrophages settled and attached to the
surface of surrounding cardiomyocytes (Movie 1, Figure 24). When stimulated at
1 Hz, the normal myocyte sarcomeric shortening was depressed approximately
50% from baseline (4.8 ± 1.9 vs 10.5 ± 2.1% shortening) and the duration of
contraction increased. (Figure 24 Lower)
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Figure 24. Upper: Movie of normal cardiomyocyte contraction at 1 Hz in na·ive
and macrophage-attached cell. Lower: Representative contraction trace
depicting both contractile depression and lengthening of the time of contraction
upon macrophage attachment.
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LPS-Stimu/ated Macrophages cause Myocyte Dysfunction in a Juxtacrine
but not Paracrine Manner

While it was an important finding that macrophage attachment to myocytes
induced contractile dysfunction, it was equally important to determine whether
these cells can exert detrimental effects in a paracrine fashion in the absence of
attachment. This is especially important in the setting of the failing heart, where
infiltrating cells mayor may not be in direct contact with a given cardiomyocyte.
In fact, in Aim 1 we have shown that while macrophages infiltrate the failing heart
and are active, they do so in small but sufficient numbers. Therefore, one could
conclude that macropahges are able to either: 1) exert influences in small
numbers via paracrine effects in the local microenvironment or 2) exert effects in
the

local

environment

via

process

extension

and

direct contact

with

cardiomyocytes. Sarcomeric shortening in cardiomyocytes both in close
approximation to, but not in contact with, and in direct physical contact with LPSactivated macro phages was measured via co-culture field stimulation and lonOptix imaging software.

Group data revealed that while cardiomyocyte

sarcomeric shortening was significantly depressed from baseline levels upon
direct physical contact with LPS stimulated macrophages (10.19 ±. 2.74 vs. 4.96

.±. 1.97 % shortening) there was no significant difference in the unattached group
(10.19

.±. 2.74 vs. 9.26 .±. 3.54 % shortening) despite cell-cell proximity between

macrophages and cardiomyocytes in this group. (Figure 25) This finding
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represents one of the first reports detailing the significant role of physical cell-tocell contact in mycoyte dysfunction.

Attachment
Macrophage
LPS

+
WT

WT

wr

+

+

Figure 25. Representative images and group data for myocyte sarcomeric
shortening at baseline (left), upon close proximity of macrophages but no
attachment (paracrine response , center), and upon macrophage attachment
Uuxtacrine response, right).

Importantly, no significant change in cardiomyocyte function was noted from
baseline levels when non-stimulated, na"lve macrophages were physically
attached to myocytes (data not shown).
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This important distinction clearly

implicates the role of the activated macrophage in the pathogenesis of myocyte
dysfunction and correlates closely with our previous data implicating the
activated, infiltrating peripheral blood macrophages in the pathogenesis of
cardiac dysfunction in HF.

Heart Failure-Derived Macrophages are Sufficiently Activated to Induce
Cardiomyocyte Contractile Depression

Having shown that LPS-stimulated macrophages induce contractile dysfunction,
we next examined whether tissue macrophages in heart failure are sufficiently
activated to mirror this response. As shown in Figure 26A, in the absence of cell
attachment, wild-type heart failure-derived macrophages did not depress
myocyte contraction over baseline (11.6 ± 1.3 vs. 9.6 ± 3.1 % shortening), again
suggesting the lack of a paracrine effect.
wild-type,

heart

failure-derived

However, direct physical contact of

macrophages

induced

severe

contractile

depression analogous to the effects of LPS-stimulated macrophages (4.5 ± 2.8
vs. 9.6 ± 3.1% shortening).

Figure 26B shows a representative image of

macrophage (white arrowhead) attachment to a myocyte using bright field
microscopy.
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Figure 26. A: Group myocyte contraction data reveal a significant depression in sarcomeric
shortening in the attached , WT HF-derived macrophage treated group (orange bar) (p=O.001 vs WT
HF unattached).
B: Representative example of macrophage (white arrows) attachment to
cardiomyocyte.

HF-Derived Macrophage-Myocyte Physical Interaction Induces Contractile
Dysfunction in a TNFR-Divergent Manner
As our in vivo studies (Aim 1) implicated changes in inflammatory cell-localized
TNF receptors 1 and 2 in the pathogenesis of LV remodeling from the molecular
level to gross function, we next sought to investigate TNFR specificity in the in
vitro cell co-culture model. WT, TNFR1-1- and TNFR2-1- mice were subjected to
coronary ligation or sham operation.

After 4 weeks peritoneal macrophages

were isolated via thioglycollate elucidation.

Isolated

Rr /- and R2-1-

macrophages were co-cultured with wild-type cardiomyocytes thereby yielding in
vitro replicas of our in vivo mouse models.

As seen in Figure 27 and in

corroboration with our in vivo experiments, ablation of macrophage specific
TNFR1 significantly alleviated macrophage-induced myocyte dysfunction. While
still significantly depressed from baseline levels, cardiomyocte function was
improved from WT HF macrophage attachment levels (7.06 :!:. 1.44 vs. 5.00 :!:.
1.54% shortening). Conversely and still in support of our in vivo data from Aim 1,
specific

ablation

cardiomyocyte

of

TNF

dysfunction.

receptor

2

Specifically,

exacerbated
upon

macrophage-induced

attachment

of TNFR2-1-

macrophages to WT myocytes, myocyte function significantly decreased from
both baseline and WT HF macrophage attachment levels (2.80 :!:. 0.19 vs. 9.39 :!:.
2.85 vs. 5.00 :!:. 1.54 % shortening, respectively).
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Figure 27: Attachment of wild type HF-derived macrophages imparts a significant dysfunction as
Attachment of R1 -1- HF-derived macrophages
compared to baseline cardiomyocyte function .
improves this dysfunction as compared to WT HF-derived, and attachment of R2-1- HF-derived
macro phages exacerbates the inflammatory cell derived dysfunction.

Taken together these data provide the first known report delineating the role of
inflammatory cell-specific TNF receptors on cardiomyocyte function in the in vitro
co-cultured macrophage/myocyte functional model.

Excitingly, these data

corroborate our in vivo, whole animal data thereby further implicating unique TNF
receptor-specific effects as central mediators of heart failure pathophysiology.

Heart Failure-Derived Macrophages Stimulate Cardiomyocyte Free Radical
Production

While the presented data presented implicate TNF receptors as central
mediators in the failing heart they do not uncover the mechanism by which this
dysfunction occurs. As generation of free radicals has long been studied as a
central and crucial underlying mechanism of cardiomyocyte dysfunction, we

studied the production of myocyte ROS in our model. Specifically, we examined
the immediate effects of macrophage attachment on the generation of oxygen
free radicals within the cardiomyocyte. First, LPS-stimulated macrophages were
co-cultured with DCF-Ioaded myocytes, and fluorescence was observed over the
short-term. Macrophage attachment rapidly induced myocyte ROS generation
within 15 minutes.{Figure 28) We then performed similar experiments with heart
failure derived macrophages and DCF-Ioaded myocytes. As seen in Figure 30,
analogous to the contractile responses, despite close cell-to-cell proximity, wildtype heart failure derived macrophages did not significantly induce myocyte ROS
in the absence of cell contact. Conversely, upon physical attachment, there was
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Figure 28: Attachment of wild type HF -<Jerived macro phages to wild type
cardiomyocytes induces reactive oxygen species production in the
cardiomyocyte 15 minutes post-attachment.

rapid myocyte ROS generation with an increase in DCF fluorescence, as seen in
the second row. In contrast, the increase in myocyte ROS was not evident with
the attachment of macrophages derived from TNFR1 -1- heart failure mice, as
1

seen in the third row . Finally, attachment of TNFR2- - HF macrophages induced
cardiomyocyte free radical production to the same degree as that induced by WT
HF macro phages.

Interestingly, increases in cardiomyocyte fluorescence

occurred in close approximation to the sites of macrophage attachment, as seen
in Figure 29, implying a direct, localized activation of the cardiomyocyte by the
macrophage and not a more generalized effect. The group data, confirmed the
qualitative images (Figure 31). DCF fluorescence was not significantly different
from baseline with the attachment of macrophages from wild-type sham mice (88

3.21 ±. 3.12) or with unattached wild-type heart failure macro phages (5.19 ±.
3.675). However, attachment of wild-type heart failure macrophages significantly
augmented myocyte ROS (31.25 ±. 7.92), which was abrogated with the loss of
macrophage TNFR1 (4.85 ± 2.52) and similar upon loss of macrophage TNFR2
(19.52 ± 6.94). Interestingly, additional stimulation of TNFR1-1- HF macrophages
with LPS still did not result in significant production of ROS upon attachment to
myocytes (1.857 ±. 0.60) indicating a TNFR1 inflammatory cell dependent
mechanism involved in myocyte ROS production. Hence, heart failure-derived
macrophages induced myocyte ROS in a juxtacrine and TNF receptor-dependent
manner (Figure 31). These data represent the first known report implicating the
role of inflammatory cell specific TNF receptor expression in the production of
cardiomyocyte free radical production in heart failure.
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Figure 29: Representative three dimensional computer generated color map
depicting increases in cardiomyocyte DCF fluorescence localized to areas of
macrophage attachment.
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Figure 30: Representative brightfield and DCF fluorescent pictures of cardiomyocytes at
baseline and 15 min post macrophage introduction. At top, WT HF paracrine interaction
showed no effect on cardiomyocyte free radical production. Second, upon attachment of
WT HF macrophages, myocyte free radical production drastically increased. Third , upon
attachment of TNFRV HF macrophages, no significant change was seen. Bottom, upon
attachment of TNFR2-1- HF macrophages, myocytes free radical production was elevated to
a level equivalent to WT HF macrophage attachment.
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Figure 31:
Group quantitative data reveal that upon attachment of WT HF macrophages, a
significant increase in fluorescence was observed (* p=O.0147) within the cardiomyocyte. This
increase was present to an equivalent degree upon attachment of TNFR2-1- HF macrophages
(p<O.05) but abolished upon attachment ofTNFR1 -1- macrophages (p=NS).

Wild Type, TNFR1.f-, and TNFRZ1- Macrophages Attach to Myocytes in
Equivalent Numbers
Stimulation of the membrane TNF receptor has a myriad of downstream effects
with one of the most important being the augmented production of several proinflammatory cytokines including TNF. These inflammatory mediators, are also
known modulators of cellular adhesion receptors and molecules.

Hence, it is

possible that alterations in macrophage-induced myocyte dysfunction was related
to changes in the magnitude macrophage attachment. To investigate this, we
obtained brightfield images at the initiation of macrophage/myocyte contact and
15 minutes post-attachment.

The numbers of attached macrophages was

determined in the 15 minute post-attachment group and reported as the final
number of attached macrophages. As can be seen in Figure 32 there was no
significant difference in number of macrophages attached between either the
WT, TNFR1-1·, or TNFR2-i- groups, thereby ruling out that these effects were
related to greater or fewer macrophages attached to the myocyte. Interestingly,
the average number of macrophages attached, four, has previously been
reported in our lab in separate studies and suggests a possible "maximal upper
limit" of macrophage load carrying ability by the cardiomyocyte.
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Figure 32:
Group data reveal no significant differences in number of
macrophages attached to myocytes in WT, TNFR1 -1-, or TNFR2-1- groups (p=NS).
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CONCLUSION

This study demonstrates for the first time that activated macrophages, whether
stimulated via LPS or by the HF state, induce contractile depression and
oxidative stress in a juxtacrine, but not paracrine manner. In addition, this cell-tocell contact is dependent not only upon physical contact, but also on
inflammatory cell TNF receptor signaling.

Whereas TNFR1 augments the

detrimental inflammatory cell-cardiomyocyte interaction, TNFR2 attenuates the
contractile dysfunction but has no effect on ROS production. This suggests that
analogous interactions could occur in human HF and that such juxtacrine,
receptor dependent responses may represent a therapeutic target in patients.
Upon physical attachment, activated macro phages enact detrimental cascades.
Free radical production is immediately induced within the cardiomyocyte, which,
in turn, leads to cardiomyocyte dysfunction. Whether this is the sole mechanism
of dysfunction is still not completely defined; however, this work provides an
important step in the quest for this answer. In support of this theory are reports
that oxidant radicals inhibit cardiomyocyte contraction via interference with
contractile proteins [101]. In order to fully elucidate this mechanism, future
studies could be done using antioxidant pre-loaded cardiomyocytes.

Overall,

these data provide an exciting and important piece of the heart failure puzzle and
suggest that modulation of immune cell, specifically macrophage, TNF receptor
expression may be an important part of the complex pathological mechanism of
the failing heart.
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CHAPTER VI

SUMMARY OF FINDINGS AND FUTURE DIRECTIONS

Summary of Findings

The significance of TNF and inflammation in the pathophysiology of myocardial
dysfunction is not an uniformly accepted principle.

While the preclinical data

regarding the influence of TNF in HF has been overwhelmingly positive, in that
antagonism of TNF in various animal models has shown significant protective
effects, the clinical data has not been so promising. How could the preclinical
and clinical experiments have such dichotomously opposing results? It is likely
that TNF has more complex inter and intrace"ular effects than previously
appreciated. Previous work in the Prabhu lab has delineated the dichotomous
relationship of the TNF receptors in whole body knockout animals, in that TNFR1
signaling appears detrimental and TNFR2 signaling, on some level beneficial.
This study serves to unravel the mystery of TNF even further by determining the
influence of inflammatory cell specific TNF receptor expression in HF physiology.
The data demonstrated here indicates that modulation of the TNF receptors in
the

inflammatory compartment can

have significant influence over the
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pathological processes involved in post ischemic remodeling. Specifically, loss
of TNFR1 in inflammatory cells demonstrated beneficial influences in cardiac
remodeling and many of the deleterious processes that define the pathology of
HF.

Conversely, selective loss of TNFR2 in inflammatory cells did not

significantly influence post-infarction cardiac remodeling, or inflammatory cell
activation.

Nonetheless, loss of either TNFR1 or TNFR2 in inflammatory cells improved
post-infarction survival. This is interesting given that the loss of TNFR2 does not
significantly change the phenotype observed in chronic HF. This is of further
interest in that it correlates with previously reported data [63] that showed a
similar survival benefit in TNFR1 and R2 whole body knockouts.

We also delineated the importance of inflammatory cell and myocyte juxtracrine
interactions in myocardial dysfunction and cellular damage.

We developed a

unique co-culture mechanism to study, in an in vitro manner, the interactions
between isolated myocytes and activated macrophages. This technique allows
for real time measurement of myocyte function and the generation of reactive
oxygen species in response to interactions to macro phages. Using this method
we determined that peritoneal macro phages activated by exposure to LPS
elicited myocyte contractile dysfunction and ROS generation in a juxtacrine but
not paracrine manner. This is interesting from two standpoints. First it shows
that activated inflammatory cells can induce significant myocyte dysfunction.
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Secondly, this interaction is dependent on cell-to-cell contact.
suggests that

pro-inflammatory states

in

HF

are

This finding

more than just an

epiphenomenon, and actively participate in myocardial dysfunction on the cellular
level.

Perhaps more interestingly, we found that HF derived macrophages

produced a similar level of myocyte dysfunction as LPS-stimulated cells.

Taking this one step further, we examined the selective role of TNF receptors in
In line with our findings in the in vivo

the macrophage-myocyte interactions.

model, selective loss of the TNFR1 receptor in inflammatory cells resulted in less
myocyte dysfunction and less ROS

production than inflammatory cells

possessing either both TNF receptors or those possessing only the TNFR1
receptor. When considered in conjunction with the in vivo studies our finding
demonstrates that the inflammatory cell serves as a significant source of myocyte
dysfunction observed in HF and that, at least to some extent, direct cellular
interactions between macrophages and myocytes are required for this effect to
take place. This work demonstrates the fundamental role of the inflammatory cell
in the pathophysiology of chronic HF, as well as the importance of TNF receptor
signaling in mediating these effects. Selective modulation of the TNF receptors
in the inflammatory compartment can yield dichotomous effects on cardiac
remodeling and function following myocardial injury. We have demonstrated that
inflammatory cell-localized TNFR1 exacerbates post-infarction remodeling in
chronic HF and is required for myocardial pro-inflammatory cytokine generation.
Conversely, inflammatory cell-localized TNFR2 yields modest beneficial effects.
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Future Directions

Heart failure is of paramount importance from a public health standpoint in the
U.S., in terms of both patient lives and dollars spent. There are approximately 5
million Americans living with clinically documented HF representing a large
percentage of health care expenditure, many times for repeated admissions for
the most decompensated patients.

In fact, it is the number one Medicare

discharge diagnosis. Many of these patients not only spend many of their last
months or years in a downward spiral in and out of the hospital but also face a
prognosis worse than many cancers.

It is therefore of the utmost importance to

develop new therapies to combat this malignant condition [100].

This study provides insights into the role of TNF in the failing heart. With the
robust nature of the benefit demonstrated in animal models, it is hard to believe
that some element of protection is not derived from modulation of TNF
expression and signaling.

Yet several clinical studies were overwhelmingly

negative, showing completely opposite outcomes from those expected. As has
been demonstrated in previous work in the Prabhu lab and now with this study,
all TNF signaling is not equal, and the cellular interactions and signaling
mechanisms at play are much more complicated than previously believed.
Discovery of the harmful effects of TNFR1 signaling offer ripe ground to reopen
the possibility of using TNF antagonism as a therapeutic approach to chronic HF.
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The development of selective TNFR1 blocking agents in the future could serve to
re-establish this potential mode of HF therapy.

Other options along this line

would be a method by which to negate sTNF, taking advantage of the differences
in the two receptors, as TNFR1 binds both sTNF and mTNF and TNFR2 binds
primarily mTNF. While this would not be as effective as a TNFR1 antagonist, it
would help to switch the balance more in favor of TNFR2 signaling and hopefully
improved clinical outcomes.

From a more mechanistic standpoint, our understanding of the role of
inflammation in chronic HF is still in its infancy, in that our understanding of the
inflammatory compartment and its influence on other organ systems is increasing
exponentially from day to day.

The data in this study, while unique and

groundbreaking, is an early and basic explanation of the interplay between
inflammatory cells and the failing myocardium.
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